racotumomab

Home
Ligands
racotumomab

GtoPdb Ligand ID: 7995

Synonyms: 1E10 | Vaxira®

racotumomab is an approved drug (Cuba and Argentina (2013))

Comment: Racotumomab is an anti-idiotype therapeutic cancer vaccine directed against the ganglioside N-glycolil (NGc) GM3 [2,5], which has been identified on the cell surface of malignant cells from lung [4] and breast tumours [8], melanoma [10-11], and neuroectodermal pediatric tumours [6-7,12-13]. Racotumomab is being investigated for its antineoplastic activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

No information available.

No information available.

Summary of Clinical Use
Racotumomab is approved in Cuba and Argentina for the treatment of recurrent or advanced non-small cell lung cancer (NSCLC). A Phase 3 clinical trial (NCT01460472) for advanced NSCLC is underway. A Phase 1 study (NCT01598454) in pediatric patients with tumours expressing N-glycolylated gangliosides is ongoing and includes indications such as neuroblastoma, Ewing's sarcoma, Wilm's tumor, retinoblastoma and glioma.

Summary of Clinical Use

Racotumomab is approved in Cuba and Argentina for the treatment of recurrent or advanced non-small cell lung cancer (NSCLC).
A Phase 3 clinical trial (NCT01460472) for advanced NSCLC is underway. A Phase 1 study (NCT01598454) in pediatric patients with tumours expressing N-glycolylated gangliosides is ongoing and includes indications such as neuroblastoma, Ewing's sarcoma, Wilm's tumor, retinoblastoma and glioma.

Mechanism Of Action and Pharmacodynamic Effects
Monoclonal antibodies that mimic gangliosides highly expressed on tumour cells are able to elicit circulating antibodies specific to the corresponding ganglioside when they are injected into syngeneic or xenogeneic animals [3,9,14]. Racotumomab is one such antibody, and induces the patient's immune system to generate a response against the cancer-specific ganglioside GM3 [1], with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.

Mechanism Of Action and Pharmacodynamic Effects

Monoclonal antibodies that mimic gangliosides highly expressed on tumour cells are able to elicit circulating antibodies specific to the corresponding ganglioside when they are injected into syngeneic or xenogeneic animals [3,9,14]. Racotumomab is one such antibody, and induces the patient's immune system to generate a response against the cancer-specific ganglioside GM3 [1], with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.